Published in Curr Opin Oncol on May 01, 2012
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma | NCT01223027
Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma | NCT01185366
A Phase II Study to Treat Subjects With Advanced Renal Cell Carcinoma | NCT00422019
A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer | NCT02019693
Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results. J Immunother Cancer (2015) 1.62
Diverse mechanisms of AKT pathway activation in human malignancy. Curr Cancer Drug Targets (2013) 1.33
Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment. Fam Cancer (2014) 1.09
PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection. Cancer Immunol Res (2013) 1.06
Sunitinib prevents cachexia and prolongs survival of mice bearing renal cancer by restraining STAT3 and MuRF-1 activation in muscle. Oncotarget (2015) 0.93
The role of surgery for metastatic renal cell carcinoma in the era of targeted therapies. World J Urol (2013) 0.84
NF-κB inhibition by bortezomib permits IFN-γ-activated RIP1 kinase-dependent necrosis in renal cell carcinoma. Mol Cancer Ther (2013) 0.82
Ovatodiolide Targets β -Catenin Signaling in Suppressing Tumorigenesis and Overcoming Drug Resistance in Renal Cell Carcinoma. Evid Based Complement Alternat Med (2013) 0.82
High-throughput simultaneous screen and counterscreen identifies homoharringtonine as synthetic lethal with von Hippel-Lindau loss in renal cell carcinoma. Oncotarget (2015) 0.81
ALK-Positive Renal Cell Carcinoma in a Large Series of Consecutively Resected Korean Renal Cell Carcinoma Patients. Korean J Pathol (2013) 0.81
The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: a new pharmacodynamic marker? PLoS One (2015) 0.81
Cellular inhibitor of apoptosis protein 1 (cIAP1) stability contributes to YM155 resistance in human gastric cancer cells. J Biol Chem (2015) 0.76
Identification of patient-specific and tumor-shared T cell receptor sequences in renal cell carcinoma patients. Oncotarget (2017) 0.75
Oncological and functional outcomes of salvage renal surgery following failed primary intervention for renal cell carcinoma. Int Braz J Urol (2015) 0.75
Global cancer statistics. CA Cancer J Clin (2011) 185.92
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med (2007) 39.39
Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med (2007) 30.94
Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin (2011) 30.81
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med (2007) 24.19
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet (2008) 19.58
The tuberous sclerosis complex. N Engl J Med (2006) 13.53
Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature (2011) 13.30
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol (2010) 13.03
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet (2011) 12.13
Identification of the von Hippel-Lindau disease tumor suppressor gene. Science (1993) 11.95
Renal-cell carcinoma. N Engl J Med (2005) 10.17
Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer (2010) 7.25
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet (1997) 6.83
HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell (2005) 5.47
Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol (2008) 5.27
Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome. Cancer Cell (2002) 5.10
Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol (2010) 5.08
The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol (2010) 5.04
Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol (2010) 4.43
Tuberous sclerosis. Lancet (2008) 4.24
Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum Mol Genet (2005) 4.12
Targeting the c-Met signaling pathway in cancer. Clin Cancer Res (2006) 3.57
Germline SDHB mutations and familial renal cell carcinoma. J Natl Cancer Inst (2008) 2.89
Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents. Am J Pathol (2001) 2.68
Birt-Hogg-Dubé syndrome, a genodermatosis associated with spontaneous pneumothorax and kidney neoplasia, maps to chromosome 17p11.2. Am J Hum Genet (2001) 2.68
Evaluation and management of renal tumors in the Birt-Hogg-Dubé syndrome. J Urol (2005) 2.33
Synergistic cooperation of TFE3 and smad proteins in TGF-beta-induced transcription of the plasminogen activator inhibitor-1 gene. Genes Dev (1998) 2.29
Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1alpha stabilization by glucose-dependent generation of reactive oxygen species. Mol Cell Biol (2009) 2.27
Kidney-targeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys. J Natl Cancer Inst (2008) 2.25
The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels. Cancer Cell (2011) 2.12
Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol (2009) 2.05
TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. Cancer Res (2007) 1.93
Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network. Ann Oncol (2010) 1.65
Specific loss of chromosomes 1, 2, 6, 10, 13, 17, and 21 in chromophobe renal cell carcinomas revealed by comparative genomic hybridization. Am J Pathol (1994) 1.62
Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI). J Support Oncol (2006) 1.61
Tuberous sclerosis-associated renal cell carcinoma. Clinical, pathological, and genetic features. Am J Pathol (1996) 1.52
Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF- D levels decrease. PLoS One (2011) 1.48
Development and validation of a scale to measure disease-related symptoms of kidney cancer. Value Health (2007) 1.45
Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors. PLoS Genet (2011) 1.43
Xp11 translocation renal cell carcinoma (RCC): extended immunohistochemical profile emphasizing novel RCC markers. Am J Surg Pathol (2010) 1.39
A distinctive pediatric renal neoplasm characterized by epithelioid morphology, basement membrane production, focal HMB45 immunoreactivity, and t(6;11)(p21.1;q12) chromosome translocation. Am J Pathol (2001) 1.27
Survival analysis of 130 patients with papillary renal cell carcinoma: prognostic utility of type 1 and type 2 subclassification. Urology (2007) 1.26
Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma. Cancer (2010) 1.19
Xp11 translocation renal cell carcinoma. Pathology (2010) 1.18
Transcription factor E3 and transcription factor EB renal cell carcinomas: clinical features, biological behavior and prognostic factors. J Urol (2010) 1.16
Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series. BJU Int (2011) 1.10
Genomic expression and single-nucleotide polymorphism profiling discriminates chromophobe renal cell carcinoma and oncocytoma. BMC Cancer (2010) 1.08
Update on targeted therapies for clear cell renal cell carcinoma. Curr Opin Oncol (2011) 1.08
A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma. BJU Int (2010) 1.03
Targeted therapies for non-clear renal cell carcinoma. Target Oncol (2010) 1.02
Epithelioid angiomyolipoma of the kidney. Pathol Int (2009) 0.92
Overexpression of KIT (CD117) in chromophobe renal cell carcinoma and renal oncocytoma. Am J Clin Pathol (2004) 0.89
The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol (2010) 5.04
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol (2012) 2.61
The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels. Cancer Cell (2011) 2.12
UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer. Cancer Genet Cytogenet (2010) 2.06
Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management. J Clin Oncol (2013) 1.96
Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer. J Urol (2007) 1.86
Molecular diagnosis and therapy of kidney cancer. Annu Rev Med (2010) 1.82
Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics. Clin Cancer Res (2007) 1.64
Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells. J Clin Invest (2008) 1.58
Expanding the morphologic spectrum of adult biphasic renal tumors--mixed epithelial and stromal tumor of the kidney with focal papillary renal cell carcinoma: case report and review of the literature. Int J Surg Pathol (2013) 1.52
Renal cell carcinoma with metastases to the gallbladder: four cases from the National Cancer Institute (NCI) and review of the literature. Urol Oncol (2011) 1.48
Genetic basis of cancer of the kidney: disease-specific approaches to therapy. Clin Cancer Res (2004) 1.45
Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer. J Urol (2012) 1.45
Low suspicion lesions on multiparametric magnetic resonance imaging predict for the absence of high-risk prostate cancer. BJU Int (2012) 1.42
Sarcomatoid renal cell carcinoma: a comprehensive review of the biology and current treatment strategies. Oncologist (2012) 1.33
Hereditary kidney cancer: unique opportunity for disease-based therapy. Cancer (2009) 1.32
Renal medullary carcinoma: molecular, immunohistochemistry, and morphologic correlation. Am J Surg Pathol (2013) 1.15
In vitro and in vivo evidence of PNH cell sensitivity to immune attack after nonmyeloablative allogeneic hematopoietic cell transplantation. Blood (2003) 1.12
Update on targeted therapies for clear cell renal cell carcinoma. Curr Opin Oncol (2011) 1.08
Evolving therapeutic targets in renal cell carcinoma. Curr Opin Oncol (2013) 1.08
Chronic GVHD and pretransplantation abnormalities in pulmonary function are the main determinants predicting worsening pulmonary function in long-term survivors after stem cell transplantation. Biol Blood Marrow Transplant (2006) 1.04
Outcomes of patients with surgically treated bilateral renal masses and a minimum of 10 years of followup. J Urol (2012) 1.03
Targeted therapies for non-clear renal cell carcinoma. Target Oncol (2010) 1.02
Renal cell carcinoma: molecular biology and targeted therapy. Curr Opin Oncol (2014) 1.01
Mechanisms of disease: the role of heat-shock protein 90 in genitourinary malignancy. Nat Clin Pract Urol (2006) 0.98
Multiple painful cutaneous nodules and renal mass. J Am Acad Dermatol (2006) 0.93
Engraftment syndrome after nonmyeloablative allogeneic hematopoietic stem cell transplantation: incidence and effects on survival. Biol Blood Marrow Transplant (2005) 0.93
Green fluorescent protein expression in dendritic cells enhances their immunogenicity and elicits specific cytotoxic T-cell responses in humans. Exp Hematol (2004) 0.92
Gleason 6 Prostate Cancer: Translating Biology into Population Health. J Urol (2015) 0.91
Impact of ischemia and procurement conditions on gene expression in renal cell carcinoma. Clin Cancer Res (2012) 0.90
Aerobic glycolysis: a novel target in kidney cancer. Expert Rev Anticancer Ther (2013) 0.89
Non-clear cell renal cancer: disease-based management and opportunities for targeted therapeutic approaches. Semin Oncol (2013) 0.89
Components of Hospital Perioperative Infrastructure Can Overcome the Weekend Effect in Urgent General Surgery Procedures. Ann Surg (2015) 0.89
Impact of genetics on the diagnosis and treatment of renal cancer. Curr Urol Rep (2011) 0.87
Intravenous therapies for castration-resistant prostate cancer: toxicities and adverse events. Urol Oncol (2011) 0.85
Robot-assisted laparoscopic partial adrenalectomy for pheochromocytoma: the National Cancer Institute technique. Eur Urol (2011) 0.84
Molecular sub-classification of renal epithelial tumors using meta-analysis of gene expression microarrays. PLoS One (2011) 0.83
Treatment of relapsed blast-phase Philadelphia-chromosome-positive leukaemia after non-myeloablative stem-cell transplantation with donor lymphocytes and imatinib. Lancet Oncol (2005) 0.83
Partial adrenalectomy minimizes the need for long-term hormone replacement in pediatric patients with pheochromocytoma and von Hippel-Lindau syndrome. J Pediatr Surg (2012) 0.82
Targeting the mTOR pathway in Chromophobe Kidney Cancer. J Cancer (2012) 0.82
Targeted for destruction: the molecular basis for development of novel therapeutic strategies in renal cell cancer. J Clin Oncol (2004) 0.81
Adrenal nodular hyperplasia in hereditary leiomyomatosis and renal cell cancer. J Urol (2012) 0.79
Differential genetic expression in large versus small clear cell renal cell carcinoma: results from microarray analysis. J Cancer (2011) 0.79
Successful laser treatment of vandetanib-associated cutaneous pigmentation. Arch Dermatol (2011) 0.78
Molecular pathways in renal cell carcinoma: recent advances in genetics and molecular biology. Curr Opin Oncol (2015) 0.77
Targeted therapies: treating advanced kidney cancer-miles to go before we sleep. Nat Rev Clin Oncol (2013) 0.76
Feasibility and outcomes of laparoscopic renal intervention after prior open ipsilateral retroperitoneal surgery. J Endourol (2013) 0.75
Editorial comment. J Urol (2010) 0.75
Impact of Post-Hospital Syndrome on Outcomes Following Elective, Ambulatory Surgery. Ann Surg (2016) 0.75
High-dose chemotherapy and allogeneic immunotherapy. Lancet (2005) 0.75
Long-term persistence of nonpathogenic clonal chromosome abnormalities in donor hematopoietic cells after allogeneic stem cell transplantation. Cancer Genet Cytogenet (2009) 0.75
Positron emission tomography for lymphoma staging: tissue remains the issue. J Natl Cancer Inst (2005) 0.75
Renal cell carcinoma: molecular characterization and evolving treatment paradigms. Curr Opin Oncol (2017) 0.75
Three-dimensional reconstruction volume: a novel method for volume measurement in kidney cancer. J Endourol (2014) 0.75
Robot-assisted renal tumor enucleo-resection in patients with a solitary kidney. Can J Urol (2015) 0.75